Trial Profile
A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2016
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Dec 2014 New trial record